Browsing Category
Pharma Industry News
4741 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Novavax offloads Maryland site to AstraZeneca for $59.8m—what does it mean for both companies?
Find out how Novavax’s Gaithersburg site transfer to AstraZeneca for $59.8M fits into its strategic refocus and what this means for future manufacturing shifts.
Are ultra‑rapid psychedelics becoming the gold standard for in‑clinic mental health therapy?
Ultra‑rapid psychedelics may redefine depression care with fast, outpatient‑compatible treatments. Explore clinical data, delivery models and commercial potential.
Is Island Pharmaceuticals (ASX: ILA) set for a breakout? Galidesivir awaits critical FDA decision
Island Pharmaceuticals secures FDA response timeline for Galidesivir. Find out how it may accelerate Marburg approval under the Animal Rule pathway.
Positive CHMP opinion sets stage for GSK’s ready-to-use Shingrix syringe approval in Europe
GSK receives CHMP green light for Shingrix prefilled syringe. Learn how this vaccine format could simplify shingles protection across Europe.
CSL Seqirus data show cell-based flu vaccine provides 20% stronger protection against lab-confirmed influenza
Find out how CSL Seqirus’s real-world data reveal a 20% protection boost for its cell-based flu vaccine over traditional egg-based shots.
Nano-Mupirocin breakthrough: Revium Rx targets MRSA and VRE with next-generation antibiotic innovation
Find out how Revium Rx’s Nano-Mupirocin could redefine antibiotic therapy against MRSA and VRE and reshape the global antimicrobial resistance market.
Crystalys Therapeutics doses first patients in Fortress Biotech’s global Phase 3 gout trial of Dotinurad, targeting safer uric acid control
Find out how Fortress Biotech’s Dotinurad is advancing in global Phase 3 trials and why it could redefine gout therapy worldwide.
QRX003 by Quoin Pharmaceuticals earns FDA orphan drug designation, signaling hope for Netherton Syndrome patients
Find out how Quoin Pharmaceuticals is changing rare-disease treatment today with its QRX003 orphan drug win — read more now!
Minerva Neurosciences gains up to $200m to advance Roluperidone toward FDA approval and U.S. market launch
Minerva Neurosciences secures up to $200 million to fund a new Phase 3 trial of Roluperidone and prepare for a potential U.S. launch. Find out what’s next.
After AbbVie took bretisilocin, what’s next for Gilgamesh Pharma’s neuropsychiatric pipeline?
Gilgamesh Pharma, newly spun out from the AbbVie deal, holds a promising psychiatric drug pipeline. Here's what the industry should expect next.